Gene therapy for prostate cancer

Seminars in Cancer Biology

Volumn 8, Issue 1, 1997, Pages 3-9

  Bower, Mark ^a   Waxman, Jonathan ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Gene therapy; Prostate cancer

Indexed keywords

6 THIOXANTHINE; CANCER VACCINE; COMPLEMENTARY RNA; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPOSOME; PHOSPHORIBOSYLTRANSFERASE; PROTEIN BCL 2; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; CYTOTOXICITY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC MANIPULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MORTALITY; NONHUMAN; NUCLEOTIDE METABOLISM; ONCOGENE; PROSTATE CANCER; RAT; REVIEW; TISSUE SPECIFICITY; TRANSGENE; VIRUS GENE;

EID: 0031076351     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1997.0055     Document Type: Article

References (35)

1. 1. Vesalainen S, Lipponen P, Talja M, Syrjanen K (1994) Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 30a:1797-1803
2. 2. Beckett M, Wright G (1995) Characterisation of a prostate carcinoma mucin-like antigen (PMA). Int J Cancer 62:703-710
3. 3. Wright G, Beckett M, Lipford G, Haley C, Schellhammer P (1991) A novel prostate carcinoma-associated glycoprotein complex (PAC) recognised by monoclonal antibody TURP-27. Int J Cancer 47:717-725
4. 4. Brenner P, Rettig W, Sanz-Moncasi M et al (1995) TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. J Urol 153:1575-1579
5. 5. Chen M, Sikes R, Troncoso P, Lin S-H, von Eschenbach A, Chung L (1996) PAGE and GAGE-7 are novel genes expressed in the LnCaP prostatic carcinogenesis model that share homology with melanoma associated antigens. J Urol 155:624A
6. 6. Sanda MG, Restifo NP, Walsh JC et al (1995) Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87:280-285
7. 7. Vieweg J, Rosenthal FM, Bannerji R et al (1994) Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54:1760-1765
8. 8. Sanda MG, Ayyagari SR, Jaffee EM et al (1994) Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151:622-628
9. 9. Neda H, Wu CH, Wu GY (1991) Chemical modification of an ecotropic murine leukemia virus results in redirection of its target cell specificity. J Biol Chem 266:14143-14146
10. 10. Kasahara N, Dozy AM, Kan YW (1994) Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266:1373-1376
11. 11. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J (1991) The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endrocrinol 5:1921-1930
12. 12. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD (1994) Expression of the prostate-specific membrane antigen. Cancer Res 54:1807-1811
13. 13. Pang S, Taneja S, Dardashti K et al (1995) Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther 6:1417-1426
14. 14. Franklin J, Pang S, Sawyer C et al (1996) Prostate specific gene therapy using a novel PSA promoter: in vivo studies. J Urol 155:436A
15. 15. Bookstein R, Rio P, Madreperla S, Hong F, Allred C, Grizzle W (1990) Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 87:7762-7766
16. 16. Phillips SM, Barton CM, Lee SJ et al (1994) Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 70:1252-1257
17. 17. Bookstein R, Shew JY Chen PL, Scully P, Lee WH (190) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715
18. 18. Yang C, Cirielli C, Capogrossi MC, Passaniti A (1995) Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55:4210-4213
19. 19. Eastham JA, Hall SJ, Sehgal I et al (1995) In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151-5155
20. 20. Umbas R, Schalken JA, Aalders TW et al (1992) Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52:5104-5109
21. 21. Umbas R, Isaacs WB, Bringuier PP et al (1994) Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54:3929-3933
22. 22. Kleinerman DI, Troncoso P, Lin SH et al (1995) Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res 55:1215-1220
23. 23. Kleinerman DI, Zhang WW, Lin SH, Nguyen TV, von Eschenbach AC, Hsieh JT (1995) Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. Cancer Res 55:2831-2836
24. 24. Veldscholte J, Ris-Stalpers C, Kuiper GGLM et al (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCAP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540
25. 25. Newmark JR, Hardy DO, Tonb DC et al (1992) Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89:6319-6323
26. 26. Suzuki H, Sato N, Watabe Y, Masai M, Seino SJS (1993) Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759-765
27. 27. Cullig Z, Hobisch A, Cronauer MV et al (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550
28. 28. Gaddipati JP, McLeod DG, Heidenberg HB et al (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861-2864
29. 29. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A (1993) Androgen-induced inhibition f cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA [published erratum appears in Cancer Res 1995; 55:719]. Cancer Res 53:1304-1311
30. 30. Fukumoto M, Shevrin DH, Roninson IB (1988) Analysis of gene amplification in human tumor cell lines. Proc Natl Acad Sci USA 85:6846-6850
31. 31. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, CA O (1987) Enhanced expression of the c-myc proto-oncogene in high-grade human prostate cancer. Prostate 11:327-337
32. 32. Steiner M, Anthony C, Lu Y, Smith L, Moses H, Holt J (1996) Gene therapy for the treatment of advanced prostate cancer by in vivo transduction with prostate targeted retroviral vectors expressing antisense C-MFCRNA. J Urol 155:340A
33. 33. McDonnell TJ, Troncoso P, Brisbay SM et al (1992) Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
34. 34. Olsson C, Buttyan R (1996) Cleavage of the mRNA for the proto-oncogene BCL-2 by a hammerhead ribozyme. J Urol 155:339A
35. 35. Eastham JA, Chen SH, Sehgal I et al (1996) Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7:515-523